HCC
Conditions
Interventions
Analgesic drug treatment cohort:Analgesic drug intervention
TEAS combined with analgesic treatment cohort:TEAS combined with analgesic intervention
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)Patients who meet the Western medical diagnostic criteria for HCC, are classified as liver depression and spleen deficiency syndrome in traditional Chinese medicine [24], and have no surgical plans in the past 14 days; (2) The patient's age should be between 18 and 80 years old, with no gender restrictions. (3) The NRS score is =4, and there is persistent pain; (4) The Child Pugh score is A or B; (5) There is liver cancer-related pain, located in the right costal region or below the xiphoid process; (6) Expected survival period of more than 3 months; (7) The patient is conscious and capable of estimating their own pain, quality of life, etc. (8) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Other physiological or pathological pain; (2) Patients who have undergone tumor surgery within the past 3 to 6 months; (3) Recently, there have been severe complications of liver cancer, such as massive hemorrhage caused by the rupture of liver cancer nodules, hepatic encephalopathy, intractable ascites, gastrointestinal bleeding, liver failure, and severe infections that are difficult to control; (4) Patients with severe primary diseases such as cardiovascular and cerebrovascular, kidney, lung, and hematopoietic system disorders; (5) People with allergic constitutions or those allergic to multiple medications; (6) Suffering from serious acute or chronic organic diseases or mental disorders; (7) Patients with skin damage at local acupoints; (8) Pregnant and lactating women; (9) Patients with pacemakers. (10) The treatment and assessment of the cycle were lacking (the prospective stage treatment records and follow-up were less than 6 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS score for liver pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| BPI-Q3 Q4 Q5 ;Dosage of analgesics;Frequency of gastrointestinal side effects of opioids;Comprehensive quality of life assessment,Including Karnofsky Performance Status Scale (KPS) and Quality of Life Scale-Liver Cancer (QOL-LC);Serum TRPA1, tumor necrosis factor-a (TNF-a), 5-hydroxytryptamine (5-HT), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-1ß (IL-1ß); | — |
Countries
China
Contacts
Public Contactlijing
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed